Program Overview
The NCCN Oncology Research Best Practices Conference will be a two-day conference focusing on educating participants in the regulatory aspects of research and identifying areas in the clinical trial process where improvements can be made. This conference is designed to be interactive through the use of panel discussions and smaller breakout sessions. Ample opportunities will exist for attendees to network with peers and get important questions and concerns addressed throughout the entire two-day conference.

Program Objectives

Identify best practices for improving the operational processes related to conducting oncology research including contracting, budgeting, resource allocation, adverse event reporting. benchmarking, and data management and monitoring
Identify best practices for maintaining and improving regulatory compliance in oncology research on federal, state, and local levels
Promote dialogue to generate tools and resources to improve oncology research processes

Target Audience
This two-day program is designed to meet the needs of oncology researchers, research nurses, institutional review board professionals, research administrators, academics, ethicists, government regulators, and industry sponsors.

Program Agenda – Monday, October 26, 2009

7:30 AM	Registration and Continental Breakfast
8:30 � 8:50 AM	Welcome and Conference Overview Maurie Markman, MD The University of Texas M. D. Anderson Cancer Center
8:55 � 9:25 AM	Keynote Address: Major Issues in Conducting Clinical Trials Mark Barnes, JD Huron Consulting Group, Inc.
9:30 �10:30 AM	Plenary Session: Intellectual Property Issues Wesley D. Blakeslee, JD Johns Hopkins University
10:35 � 10:50 AM	Break
10:55 AM � 12:55 PM	Panel Discussion: Budget, Billing, and Reimbursement Issues Moderator: Clifford Goodman, PhD The Lewin Group Panel: Alice MacDermott, JD University of Michigan Ryan D. Meade, JD Meade & Roach, LLP Paul Papagni, JD, CIP The University of Texas M. D. Anderson Cancer Center
1:00 � 1:55 PM	Lunch
2:00 � 3:25 PM	Interactive Breakout Workshops Biospecimens, Biorepositories, & Molecular Annotation Best Practices Donald A. Bergstrom, MD, PhD Merck & Co., Inc. Carolyn Compton, MD, PhD National Cancer Institute Peter Shaw, PhD Merck & Co., Inc. Issues in the Ethical Conduct of International and Multi-Institutional Research Edward Bartlett, PhD Office for Human Research Protection Best Practices in Contracting Raymond T. Rufer , MBA, JD The University of Texas M. D. Anderson Cancer Center
3:30 PM	Adjourn

Program Agenda – Tuesday, October 27, 2009

7:00 AM	Registration and Continental Breakfast
8:00 � 10:00 AM	Panel Discussion: Comparative Effectiveness Moderator: William T. McGivney, PhD National Comprehensive Cancer Network Panel: Al B. Benson III, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Kimary Kulig, PhD Pfizer, Inc. Robert S. McDonough, MD, JD, MPP Aetna
10:05 � 11:05 AM	Plenary Session: Process Improvement for Clinical Trials Operations with an Emphasis on Trial Start-Up Jeffrey W. Clark, MD (tentative) Dana-Farber/Brigham and Women’s Cancer Center \| Massachusetts General Hospital Cancer Center
11:10 � 11:25 AM	Break
11:30 AM � 1:30 PM	Panel Discussion: Conflicts of Interest in Clinical Research Moderator: Maurie Markman, MD The University of Texas M. D. Anderson Cancer Center Panel: Robert A. Figlin, MD City of Hope Comprehensive Cancer Center Daniel F. Donovan III, JD King & Spalding Edward B Goldman, JD University of Michigan Gerald H. Sokol, MD, MSc Food and Drug Administration
1:35 � 2:30 PM	Lunch
2:35 � 4:00 PM	Interactive Breakout Workshops Management of Serious Adverse Events Kristin Bialobok, MSN, RN, CCRC, CCRA Oregon Health & Science University Knight Cancer Institute Biospecimens, Biorepositories, & Molecular Annotation Best Practices Donald A. Bergstrom, MD, PhD Merck & Co., Inc. Carolyn Compton, MD, PhD National Cancer Institute Peter Shaw, PhD Merck & Co., Inc. Issues Related to Incorporating Novel Imaging in Clinical Trials
4:05 PM	Adjourn

Agenda and faculty are subject to change.

Registration Fees
$295 – Regular Rate
$195 – NCCN Corporate Council Members
$95 – Government Employee Rate

Space is limited – Register Now!

Supporters
This Conference is supported by grants from Amgen, Millennium: The Takeda Oncology Company and sanofi-aventis, US.

Cancellation Policy
If you register for the conference and then cannot attend, a substitute attendee may be sent in your place. A $50 administration fee will be charged for each substitution. A $50 administration fee will be charged for cancellations received through October 16, 2009. After October 16, the registration fee is not refundable. This cancellation policy pertains only to conference registration.

Accommodations
NCCN has reserved a block of rooms for the evenings of October 25 and October 26 at the rate of $159, plus taxes per night, for this event at the Marriott Bethesda. Please call 800.228.9290 or 301.897.9400 to make your reservation by Friday, October 2, 2009 indicating that you are with the National Comprehensive Cancer Network (NCCN) group. NCCN has no control over hotel policy regarding transfer and cancellation policies. Please clarify all restrictions and policies at time of booking with the hotel agent.

E-mail

Mark A A Size

	Quick Links
Clinical Practice Guidelines Drugs & Biologics Compendium Chemotherapy Order Templates Educational Events CME/CE Programs For Patients: NCCN.com Find an NCCN Member Institution Clinical Practice Guidelines Find Clinical Trials Permissions Requests Case Manager Training Member Institution Profiles Clinical Practice Guidelines Drugs & Biologics Compendium Permissions Requests Supporters and Exhibitors Oncology Research Program Corporate Council Permissions Requests NCCN Academy NCCN Business Insights, Research & Analytics NCCN Flash Updates NCCN Trends Surveys Permissions Requests